142 related articles for article (PubMed ID: 25368277)
21. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial.
Witzens-Harig M; Hensel M; Unterhalt M; Herfarth K
BMC Cancer; 2011 Feb; 11():87. PubMed ID: 21352561
[TBL] [Abstract][Full Text] [Related]
22. Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy.
Campbell BA; Voss N; Woods R; Gascoyne RD; Morris J; Pickles T; Connors JM; Savage KJ
Cancer; 2010 Aug; 116(16):3797-806. PubMed ID: 20564082
[TBL] [Abstract][Full Text] [Related]
23. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy.
Guadagnolo BA; Li S; Neuberg D; Ng A; Hua L; Silver B; Stevenson MA; Mauch P
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):928-34. PubMed ID: 16243446
[TBL] [Abstract][Full Text] [Related]
24. Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Tarella C; Zanni M; Magni M; Benedetti F; Patti C; Barbui T; Pileri A; Boccadoro M; Ciceri F; Gallamini A; Cortelazzo S; Majolino I; Mirto S; Corradini P; Passera R; Pizzolo G; Gianni AM; Rambaldi A
J Clin Oncol; 2008 Jul; 26(19):3166-75. PubMed ID: 18490650
[TBL] [Abstract][Full Text] [Related]
25. Low dose radiotherapy in indolent lymphomas, enough is enough.
Haas RL
Hematol Oncol; 2009 Jun; 27(2):71-81. PubMed ID: 19266491
[TBL] [Abstract][Full Text] [Related]
26. Elective nodal irradiation (ENI) vs. involved field radiotherapy (IFRT) for locally advanced non-small cell lung cancer (NSCLC): A comparative analysis of toxicities and clinical outcomes.
Fernandes AT; Shen J; Finlay J; Mitra N; Evans T; Stevenson J; Langer C; Lin L; Hahn S; Glatstein E; Rengan R
Radiother Oncol; 2010 May; 95(2):178-84. PubMed ID: 20356642
[TBL] [Abstract][Full Text] [Related]
27. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
[TBL] [Abstract][Full Text] [Related]
28. Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma.
Seymour JF; Pro B; Fuller LM; Manning JT; Hagemeister FB; Romaguera J; Rodriguez MA; Ha CS; Smith TL; Ayala A; Hess M; Cox JD; Cabanillas F; McLaughlin P
J Clin Oncol; 2003 Jun; 21(11):2115-22. PubMed ID: 12775737
[TBL] [Abstract][Full Text] [Related]
29. [Is radiotherapy curative for stage-I and -II low-grade follicular lymphomas? The results a long-term follow-up study of patients treated at Stanford University].
Sack H
Strahlenther Onkol; 1996 Dec; 172(12):691-3. PubMed ID: 8992640
[No Abstract] [Full Text] [Related]
30. Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size.
Campbell BA; Voss N; Pickles T; Morris J; Gascoyne RD; Savage KJ; Connors JM
J Clin Oncol; 2008 Nov; 26(32):5170-4. PubMed ID: 18838714
[TBL] [Abstract][Full Text] [Related]
31. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
33. Nodal follicular lymphoma: the role of radiotherapy for stages I and II.
Heinzelmann F; Engelhard M; Ottinger H; Bamberg M; Weinmann M
Strahlenther Onkol; 2010 Apr; 186(4):191-6. PubMed ID: 20354662
[TBL] [Abstract][Full Text] [Related]
34. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M
J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681
[TBL] [Abstract][Full Text] [Related]
35. Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure.
Russo AL; Chen YH; Martin NE; Vinjamoori A; Luthy SK; Freedman A; Michaelson EM; Silver B; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2013 May; 86(1):121-7. PubMed ID: 23414765
[TBL] [Abstract][Full Text] [Related]
36. Treatment strategies in limited stage follicular NHL.
Hoppe RT
Best Pract Res Clin Haematol; 2011 Jun; 24(2):179-86. PubMed ID: 21658617
[TBL] [Abstract][Full Text] [Related]
37. Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma.
Besa PC; McLaughlin PW; Cox JD; Fuller LM
Cancer; 1995 May; 75(9):2361-7. PubMed ID: 7712449
[TBL] [Abstract][Full Text] [Related]
38. Does the addition of involved field radiotherapy to high-dose chemotherapy and stem cell transplantation improve outcomes for patients with relapsed/refractory Hodgkin lymphoma?
Kahn S; Flowers C; Xu Z; Esiashvili N
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):175-80. PubMed ID: 20732769
[TBL] [Abstract][Full Text] [Related]
39. A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait.
El-Galaly TC; Bilgrau AE; de Nully Brown P; Mylam KJ; Ahmad SA; Pedersen LM; Gang AO; Bentzen HH; Juul MB; Bergmann OJ; Pedersen RS; Nielsen BJ; Johnsen HE; Dybkaer K; Bøgsted M; Hutchings M
Br J Haematol; 2015 May; 169(3):435-44. PubMed ID: 25709094
[TBL] [Abstract][Full Text] [Related]
40. Therapy of nodal Follicular Lymphoma (WHO grade 1/2) in clinical stage I/II using response adapted Involved Site Radiotherapy in combination with Obinutuzumab (Gazyvaro) - GAZAI Trial (GAZyvaro and response adapted Involved-site Radiotherapy): a study protocol for a single-arm, non-randomized, open, national, multi-center phase II trial.
König L; Dreyling M; Dürig J; Engelhard M; Hohloch K; Viardot A; Witzens-Harig M; Kieser M; Klapper W; Pott C; Herfarth K
Trials; 2019 Aug; 20(1):544. PubMed ID: 31470902
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
